Homburger advised Windward Bio Group — a Swiss-based biotechnology specialist in advanced immunological diseases — in connection with a licensing agreement between the company’s affiliate, LE2025 Therapeutics, and Qyuns Therapeutics Co. for the development
Tags :Homburger
Homburger advised Aris Mining Corporation on its acquisition of the remaining 49% interest in the Soto Norte joint venture in Colombia from MDC Industry Holding Company (Mubadala). Pursuant to the deal, Aris Mining Corporation owns 100% of
L’Oréal acquired an additional 10% stake in Galderma. In connection with the transaction, Bär & Karrer advised the buyer, Niederer Kraft Frey (NKF) supported Galderma, while Homburger represented EQT, leader in a consortiun
Homburger advised Roche throughout its senior notes issuance, for an aggregate principal amount of USD 1.9 bn. The notes in question were issued by Roche Holdings, Inc. and guaranteed by Roche Holding Ltd. The issuance encompasses
Homburger served as special Swiss counsel to UniCredit Bank in connection with its role as mandated lead arranger for the USD 1.1 bn borrowing base credit facilities to Neumann Gruppe, the holding company of globally active
Homburger advised UBS Group and UBS on their all-cash tender offers to repurchase various series of outstanding debt instruments in an aggregate principal amount of USD 7.7 bn. The context UBS Group closed its tender offer
Homburger advised UBS throughout its issuance of EUR 750 million in floating rate notes due 2027. The bank, acting through its London branch, completed the operation under its Euro Note Programme. The Homburger team Capital markets’ Stefan
Homburger advised NVentures – NVIDIA’s venture capital arm – in connection with its role as investor in Flexion Robotics’s USD 50 million series A funding round. Beyond NVentures, the Zurich-based technology company received support from DST
Homburger advised UBS, acting through its Stamford branch, on a USD 750m offering in floating rate senior notes. The notes in question, issued under UBS’ medium-term notes program, are due in 2027. The Homburger team Stefan
Homburger advised CDR-Life on a new global licensing agreement with Boehringer Ingelheim, aimed at the development of an antibody-based molecule for autoimmune diseases. The context The agreement – which follows the companies’ collaboration on an investigational
